Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 103
Filter
1.
Actual. osteol ; 17(2): 92-103, 2021. ilus, tab
Article in Spanish | LILACS, BINACIS, UNISALUD | ID: biblio-1370258

ABSTRACT

El carcinoma paratiroideo (CP) es una neoplasia maligna con una incidencia de 0,015 cada 100.000 habitantes por año. Representa el 1% de los diagnósticos de hiperparatiroidismo primario y se manifiesta entre la 4.a y 5.a década de la vida, con una incidencia similar entre hombres y mujeres. La etiología del CP es incierta, ha sido asociada a formas esporádicas o familiares. Está caracterizado por altos niveles séricos de calcio y PTH y el desafío clínico-quirúrgico es el diagnóstico diferencial con otras entidades benignas como el adenoma o la hiperplasia de paratiroides. Aunque el diagnóstico de certeza es anatomopatológico, la sospecha clínica y el uso de métodos de baja complejidad (ecografía) con operadores avezados permite una correcta localización y abordaje pertinente del paciente para dirigir el tratamiento quirúrgico adecuado (resección en bloque) evitando persistencias y recurrencias de enfermedad. Se presenta el caso clínico de un paciente masculino que ingresa por síndrome de impregnación asociado a hipercalcemia, su abordaje diagnóstico, tratamiento y manejo interdisciplinario con discusión y revisión bibliográfica. (AU)


Parathyroid carcinoma (CP) is a malignant disease with an incidence of 0.015 per 100,000 inhabitants per year. It accounts for 1% of primary hyperparathyroidism diagnoses and occurs between the 4th and 5th decade of life, with a similar incidence between men and women. The etiology of CP is uncertain and has been associated with sporadic or family forms. CP is characterized by high serum calcium and PTH levels and the clinical-surgical challenge is the differential diagnosis with other benign entities such as parathyroid adenoma or hyperplasia. Although the diagnosis of certainty is achieved by pathological anatomy examination, the clinical suspicion and the use of low complexity methods (ultrasound) by experienced operators allows a correct localization and a patient-specific approach to direct the appropriate surgical treatment (block resection), avoiding persistence and recurrences of disease. The clinical case of a male patient admitted for severe hypercalcemia with multiple organ disfunction, the diagnostic approaches, treatment, and interdisciplinary management, together with review and discussion of the current literature are presented. (AU)


Subject(s)
Humans , Male , Middle Aged , Parathyroid Neoplasms/complications , Parathyroid Neoplasms/etiology , Parathyroid Neoplasms/diagnostic imaging , Hyperparathyroidism, Primary/complications , Hyperparathyroidism, Primary/diagnosis , Hyperparathyroidism, Primary/etiology , Parathyroid Hormone/blood , Parathyroid Neoplasms/surgery , Parathyroid Neoplasms/pathology , Calcitriol/administration & dosage , Calcium Gluconate/administration & dosage , Radiography , Tomography , Calcium/administration & dosage , Ultrasonography , Diagnosis, Differential , Hypercalcemia/blood
2.
Actual. osteol ; 16(1): 77-82, Ene - abr. 2020. ilus
Article in Spanish | LILACS | ID: biblio-1140152

ABSTRACT

Introducción. El hipoparatiroidismo es una enfermedad caracterizada por la ausencia o concentraciones inadecuadamente bajas de hormona paratiroidea (PTH), que conduce a hipocalcemia, hiperfosfatemia y excreción fraccional elevada de calcio en la orina. Las calcificaciones del sistema nervioso central son un hallazgo frecuente en estos pacientes. Caso clínico. Mujer de 56 años con antecedente de hipotiroidismo, que ingresó por un cuadro de 6 días de evolución caracterizado por astenia, parestesias periorales y movimientos anormales de manos y pies. Las pruebas de laboratorio demostraron hipocalcemia, hiperfosfatemia y niveles bajos de hormona paratiroidea. Se realizó una tomografía computarizada de cráneo que mostró áreas bilaterales y simétricas de calcificaciones en hemisferios cerebelosos, ganglios basales y corona radiata. No se evidenciaron trastornos en el metabolismo del cobre y hierro. Se estableció el diagnóstico del síndrome de Fahr secundario a hipoparatiroidismo y se inició tratamiento con suplementos de calcio y vitamina D con evolución satisfactoria. Discusión. El síndrome de Fahr es un trastorno neurológico caracterizado por el depósito anormal de calcio en áreas del cerebro que controlan la actividad motora. Se asocia a varias enfermedades, especialmente, hipoparatiroidismo. La suplementación con calcio y vitamina D con el objetivo de normalizar los niveles plasmáticos de estos cationes es el tratamiento convencional. (AU)


Introduction. Hypoparathyroidism is a disease characterized by absence or inappropriately low concentrations of circulating parathyroid hormone, leading to hypocalcaemia, hyperphosphataemia and elevated fractional excretion of calcium in the urine. Central nervous system calcifications are a common finding in these patients. Case report. 56-year-old woman with a history of hypothyroidism who was admitted for a 6-day course of illness characterized by asthenia, perioral paresthesias, and abnormal movements of the hands and feet. Laboratory tests showed hypocalcemia, hyperphosphatemia, and low parathyroid hormone levels. A cranial computed tomography was performed. It showed bilateral and symmetrical areas of calcifications in the cerebellar hemispheres, basal ganglia, and radiata crown. No disorders of copper or iron metabolism were evident. The diagnosis of Fahr syndrome secondary to hypoparathyroidism was established and treatment with calcium and vitamin D supplements was started with satisfactory evolution. Discussion. Fahr's syndrome is a neurological disorder associated with abnormal calcium deposition in areas of the brain that control motor activity. It is associated with various diseases, especially hypoparathyroidism. The conventional treatment is supplementation with calcium and vitamin D, with the aim of normalizing their plasma levels. (AU)


Subject(s)
Humans , Female , Middle Aged , Calcinosis/diagnostic imaging , Hypoparathyroidism/diagnosis , Nervous System Diseases/diagnostic imaging , Parathyroid Hormone/blood , Calcinosis/complications , Calcinosis/drug therapy , Calcitriol/administration & dosage , Calcium Carbonate/administration & dosage , Calcium Gluconate/administration & dosage , Calcium/administration & dosage , Hyperphosphatemia/blood , Hypocalcemia/blood , Hypoparathyroidism/etiology , Hypoparathyroidism/drug therapy , Nervous System Diseases/complications , Nervous System Diseases/drug therapy
3.
Arq. bras. med. vet. zootec. (Online) ; 72(1): 153-160, Jan.-Feb. 2020. tab, graf
Article in Portuguese | LILACS, VETINDEX | ID: biblio-1088926

ABSTRACT

O objetivo do estudo foi avaliar a disponibilidade de cálcio (Ca2+) a partir de duas formas farmacêuticas (oral e intravaginal) e o seu efeito sobre o metabolismo de ruminantes. O estudo foi realizado na fazenda experimental da Universidade Federal de Pelotas, foram estudadas 24 ovelhas lactantes, divididas de forma randomizada em 4 grupos: dispositivo tratamento (DT); dispositivo controle (DC); oral tratamento (OT); e oral controle (OC). Os animais tratados receberam formiato de cálcio e cloreto de magnésio, as avaliações foram realizadas após a administração dos tratamentos. Foi feita avaliação de cálcio total (CaT), magnésio (Mg), proteínas plasmáticas totais (PPT), aspartato aminotransferase (AST), gama glutamil transpeptidase (GGT), ureia, albumina e pH urinário, e realizado exame clínico em todos os animais. As concentrações séricas de CaT, CaI e Mg diferiram entre os grupos (P≤ 0,05), os animais dos grupos DT e DC, diferiram nas três avaliações, o grupo DT apresentou as maiores médias, sendo significativamente igual ao grupo OT. Não houve diferença nas concentrações séricas de PPT, AST, GGT, Albumina, Ureia e pH urinário. Conclui-se que a disponibilidade sanguínea de CaT, CaI e Mg é igual quando a administração de formiato de cálcio e magnésio é por via intravaginal ou por via oral, sem alterar outros parâmetros metabólicos avaliados.(AU)


The aim of the study was to evaluate the availability of calcium (Ca2+) from two pharmaceutical forms (oral and intravaginal) and its effect on the metabolism of ruminants. The study was carried out at the experimental farm of the Federal University of Pelotas. Twenty-four lactating ewes were randomly divided into 4 groups: treatment device (TD); control device (DC); oral treatment (OT); and oral control (OC). Treated animals received calcium formate and magnesium chloride, evaluations were performed after administration of the treatments. Total calcium (CaT), magnesium (Mg), total plasma proteins (PPT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), urea, albumin and urinary pH, and clinical examination were performed on all animals. Serum CaT, CaI and Mg levels differed between the groups (P≤ 0.05), the animals in the DT and DC groups differed in the three evaluations, the DT group had the highest mean values, being significantly equal to the OT group. There was no difference in the serum concentrations of PPT, AST, GGT, Albumin, Urea and urinary pH. In conclusion, the blood availability of CaT, CaI and Mg is the same when administration of calcium and magnesium formate is intravaginal or orally, without altering other metabolic parameters evaluated.(AU)


Subject(s)
Animals , Female , Administration, Intravaginal , Sheep/metabolism , Calcium/administration & dosage , Hypocalcemia/veterinary , Magnesium/administration & dosage
4.
Arch. latinoam. nutr ; 69(3): 131-141, sept. 2019. tab
Article in Spanish | LILACS, LIVECS | ID: biblio-1053203

ABSTRACT

La acumulación adecuada de masa ósea durante la adolescencia es un factor protector para osteoporosis y otras afecciones óseas, por tanto, resulta relevante la evaluación del consumo de calcio y de otros determinantes de la densidad mineral ósea (DMO), en adolescentes. Se evaluó el consumo de calcio, otros factores biológicos y de estilo de vida, como predictores de la DMO en adolescentes venezolanos. Se realizó un estudio transversal, correlacional en 60 adolescentes (15 a 18 años), de la cohorte 2011-2012 del Programa Igualdad de Oportunidades de la Universidad Simón Bolívar (USB). La DMO, y el consumo de calcio y bebidas antagonistas del metabolismo del calcio, se determinaron mediante un cuestionario semicuantitativo de frecuencia de alimentos; También se evaluó el estado nutricional (por índice de masa corporal) y el nivel de actividad física. En promedio, la ingesta de calcio fue adecuada (1183 mujeres y 1315 mg/d hombres) y las principales fuente de calcio fueron la leche y sus derivados. Sin embargo, el 42% de los individuos presentó un consumo de calcio por debajo de lo recomendado. Los niveles de actividad física fueron entre bajos y moderados. El 95% de los adolescentes presentaron una DMO adecuada para su edad, siendo el sexo y el consumo de calcio los principales predictores. El consumo de calcio es un determinante importante de la DMO, siendo necesario para garantizar una contribución dietética adecuada durante la adolescencia, con el fin de prevenir un riesgo de deficiencia nutricional que pueda afectar la salud ósea(AU)


The adequate accumulation of bone mass during adolescence is a protective factor against the development of osteoporosis and other bone conditions. Therefore, evaluation of the consumption of calcium and other determinants of bone mineral density (BMD) in adolescents is relevant. The consumption of calcium and other biological and lifestyle factors were evaluated as predictors of BMD in Venezuelan adolescents. A correlational cross-sectional study was conducted in a group of 60 adolescents (15-18 years old), of the 2011-2012 cohort of the Equal Opportunities Program of the Simón Bolívar University (USB). BMD, and the consumption of calcium and drinks antagonistic to calcium metabolism, were determined through a semi-quantitative food frequency questionnaire; the nutritional status (by body mass index) and the level of physical activity were also evaluated. On average, calcium intake was adequate (1183 women and 1315 mg/d men) and the main sources of calcium were milk and its derivatives. However, 42% of individuals had a calcium intake below recommended. The majority of adolescents presented BMI within normal values (78.4% women and 69.6% men). Physical activity levels were between low and moderate. 95% of adolescents presented an adequate BMD for their age, being sex and calcium consumption the main predictors. The calcium consumption is an important determinant of BMD, being necessary to ensure an adequate dietary contribution during adolescence, with the purpose of preventing a risk of nutritional deficiency that may affects bone health(AU)


Subject(s)
Humans , Male , Female , Adolescent , Osteoporosis/diagnosis , Bone Density/drug effects , Calcium/administration & dosage , Adolescent Nutrition , Dietary Sugars , Deficiency Diseases , Eating , Diet, Food, and Nutrition
5.
Actual. osteol ; 15(2): 94-102, mayo - ago. 2019. tab.
Article in Spanish | LILACS | ID: biblio-1048478

ABSTRACT

El propósito de la terapia en el desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica (IRC) consiste en restaurar el balance mineral, y, en la osteoporosis, mantener o aumentar la masa ósea. Ambas terapias tratan de evitar la fractura ósea. La mayoría de los osteoactivos están contraindicados en la insuficiencia renal crónica avanzada (estadios 4 y 5), y las terapias son empíricas. Algunos autores opinan que sin anomalías bioquímicas del desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica avanzada se podría intentar el tratamiento estándar para la osteoporosis. Antes de intentar la terapia osteoactiva se debe corregir el desorden mineral óseo que pudiera presentarse asociado a la IRC, y en la indicación del tipo de osteoactivo se sugiere seleccionar al paciente según su estado óseo. Se aconseja que la administración de los antirresortivos se realice a dosis menores con respecto a los que tienen mejor función renal junto con aportes adecuados de calcio y vitamina D, antes y durante el tratamiento para prevenir el riesgo de severas hipocalcemias y un efecto óseo excesivo. Se presenta el caso clínico de una mujer de 65 años, con diagnóstico de osteoporosis de etiología multifactorial, fractura de pelvis, múltiples fracturas vertebrales e insuficiencia renal crónica avanzada, entre otras comorbilidades, y probable enfermedad ósea adinámica. Recibió inicialmente terapia con teriparatide y luego con denosumab, complicándose con hipocalcemia asintomática. (AU)


The purpose of therapy for the bone mineral metabolism disorder associated with chronic kidney disease is to restore the mineral balance; and to maintain or increase bone mass in osteoporosis. The goal of both types of therapy is to avoid bone fractures. Most antiosteoporotic drugs are contraindicated in advanced chronic renal failure (CRF) stages 4 and 5, and the therapies are empirical. Some authors believe that without biochemical abnormalities of the mineral bone metabolism disorder associated with advanced chronic kidney disease, standard treatment for osteoporosis could be attempted. Before attempting antiosteoporotic therapy, the bone mineral disorder that may be associated with CRF must be corrected, and in the indication of the type drug it is suggested that the patient be selected according to their bone status. It is advised that the administration of anti-resorptives be performed at lower doses in individuals with poor renal function compared to those with better renal function together with adequate calcium and vitamin D, before and during treatment to prevent the risk of severe hypocalcemia, and an excessive bone effect. We present the clinical case of a 65-year-old woman with a diagnosis of osteoporosis of multifactorial etiology, pelvic fracture, multiple vertebral fractures and advanced chronic renal failure, among other comorbidities and probable adynamic bone disease. The patient received initial therapy with teriparatide and followed by denosumab administration and exhibited asymptomatic hypocalcemia. (AU)


Subject(s)
Humans , Female , Aged , Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy , Fractures, Bone/prevention & control , Osteoporosis/therapy , Chronic Kidney Disease-Mineral and Bone Disorder/complications , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/therapy , Vitamin D/administration & dosage , Vitamin D/therapeutic use , Calcium/administration & dosage , Calcium/therapeutic use , Alendronate/therapeutic use , Teriparatide/administration & dosage , Teriparatide/adverse effects , Teriparatide/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Cinacalcet/therapeutic use , Risedronic Acid/therapeutic use , Denosumab/administration & dosage , Denosumab/adverse effects , Denosumab/therapeutic use , Hypocalcemia/prevention & control
6.
Actual. osteol ; 15(1): 57-64, ene. abr. 2019. ilus., tab.
Article in Spanish | LILACS | ID: biblio-1049428

ABSTRACT

Los tratamientos para osteoporosis se indican por tiempo variable dependiendo del tipo de droga, anabólica o anticatabólica, y de la gravedad de la enfermedad. Denosumab es un anticuerpo monoclonal totalmente humano que inhibe a RANK-L evitando de esa manera la interacción entre RANKL-RANK, con la consiguiente inhibición de la formación de los osteoclastos, su activación y sobrevida. Disminuye la resorción ósea cortical y trabecular. Su administración subcutánea de 60 mg cada 6 meses al cabo de 3 años ha demostrado reducción de la resorción ósea, incremento de la densidad mineral ósea y disminución de las fracturas vertebrales, no vertebrales y de cadera. Está indicado para el tratamiento de la osteoporosis con alto riesgo de fractura. Su mecanismo de acción es reversible. Se han descripto pérdida de la DMO y elevación de los marcadores de remodelado óseo postsuspensión. Una situación clínica grave son las fracturas vertebrales múltiples postsuspensión. Este evento es infrecuente y se lo atribuye a un rebote del remodelado óseo, postulándose se postula una predisposición especial, probablemente relacionada con microRNA. Se escriben dos mujeres con osteoporosis que presentaron este cuadro. Las fracturas ocurrieron entre 7 y 10 meses posteriores a la última dosis de denosumab. Registraron elevación de C-telopéptidos y disminución de la DMO conjuntamente con las fracturas vertebrales agudas en cascada. (AU)


The duration of osteoporosis treatments depends on the drug type, anabolic or anticatabolic, and the severity of the disease. Denosumab is a fully human monoclonal antibody that inactivates RANK-L, inhibiting the RANKL-RANK interaction . This inhibits osteoclast formation, activation, and survival. It also reduces cortical and trabecular bone resorption. Subcutaneous administration of 60 mg every 6 months for 3 years has reduced bone resorption, increased bone mineral density (BMD) and decreased vertebral, non-vertebral and hip fractures. It is indicated for the treatment of osteoporosis with high risk of fracture. Denosumab mechanism of action is reversible. After discontinuation, loss of BMD and elevation of bone turnover markers have been observed. In addition, multiple vertebral fractures after the suspension of the drug have been reported. These rebound-associated vertebral fractures are rare. A special genetic predisposition related to miRNA has been proposed. Two women with this clinical presentation are described. Fractures occurred between 7 and 10 months respectively after the last dose of denosumab. They presented with an increase in circulating C-telopeptid levels and a decrease inBMD with acute multiple vertebral fractures. (AU)


Subject(s)
Humans , Female , Middle Aged , Aged , Spinal Fractures/drug therapy , Denosumab/adverse effects , Osteoporosis/drug therapy , Quality of Life , Menopause , Biomarkers , Bone Density/drug effects , Calcium/administration & dosage , Spinal Fractures/prevention & control , Charybdotoxin/analysis , Calcium Citrate/administration & dosage , Alendronate/administration & dosage , MicroRNAs/metabolism , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , RANK Ligand/drug effects , Denosumab/administration & dosage , Tobacco Smoking , Zoledronic Acid/administration & dosage , Ibandronic Acid/administration & dosage , Indapamide/administration & dosage
7.
Braz. j. otorhinolaryngol. (Impr.) ; 85(1): 63-70, Jan.-Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-984054

ABSTRACT

Abstract Introduction: In hypoparathyroidism, calcium supplementation using calcium carbonate is necessary for the hypocalcemia control. The best calcium carbonate intake form is unknown, be it associated with feeding, juice or in fasting. Objective: The objective was to evaluate the calcium, phosphorus and calcium × phosphorus product serum levels of hypoparathyroidism women after total thyroidectomy, following calcium carbonate intake in three different forms. Methods: A crossover study was carried out with patients presenting definitive hypoparathyroidism, assessed in different situations (fasting, with water, orange juice, breakfast with a one-week washout). Through the review of clinical data records of tertiary hospital patients from 1994 to 2010, 12 adult women (18-50 years old) were identified and diagnosed with definitive post-thyroidectomy hypoparathyroidism. The laboratory results of calcium and phosphorus serum levels dosed before and every 30 min were assessed, for 5 h, after calcium carbonate intake (elementary calcium 500 mg). Results: The maximum peak average values for calcium, phosphorus and calcium × phosphorus product were 8.63 mg/dL (water), 8.77 mg/dL (orange juice) and 8.95 mg/dL (breakfast); 4.04 mg/dL (water), 4.03 mg/dL (orange juice) and 4.12 mg/dL (breakfast); 34.3 mg2/dL2 (water), 35.8 mg2/dL2 (orange juice) and 34.5 mg2/dL2 (breakfast), respectively, and the area under the curve 2433 mg/dL min (water), 2577 mg/dL min (orange juice) and 2506 mg/dL min (breakfast), 1203 mg/dL min (water), 1052 mg/dL min (orange juice) and 1128 mg/dL min (breakfast), respectively. There was no significant difference among the three different tests (p > 0.05). Conclusion: The calcium, phosphorus and calcium × phosphorus product serum levels evolved in a similar fashion in the three calcium carbonate intake forms.


Resumo Introdução: No hipoparatireoidismo, a suplementação de cálcio com carbonato de cálcio é necessária para o controle da hipocalcemia. A melhor forma de ingestão de carbonato de cálcio ainda é desconhecida, seja concomitante com alimentação, no suco ou em jejum. Objetivo: Avaliar os níveis séricos de cálcio, fósforo e produto cálcio-fósforo em mulheres pós-tireoidectomia por hipoparatireoidismo, após a ingestão de carbonato de cálcio em três formas diferentes. Método: Foi realizado um estudo cruzado em pacientes com hipoparatireoidismo definitivo, avaliados em diferentes situações (em jejum, com água, suco de laranja, café da manhã, após washout de uma semana). A revisão dos prontuários dos pacientes de um hospital terciário de 1994 a 2010 identificou 12 mulheres adultas (18-50 anos), diagnosticadas com hipoparatireoidismo definitivo pós-tireoidectomia. Os resultados laboratoriais dos níveis séricos de cálcio e fósforo foram mensurados antes e a cada 30 minutos durante 5 horas, após a ingestão de carbonato de cálcio (cálcio elementar 500 mg). Resultados: Os valores de pico máximo médio de cálcio, fósforo e produto cálcio-fósforo foram 8,63 mg/dL (água), 8,77 mg/dL (suco de laranja) e 8,95 mg/dL (café da manhã); 4,04 mg/dL (água), 4,03 mg/dL (suco de laranja) e 4,12 mg/dL (café da manhã); 34,3 mg2/dL2 (água), 35,8 mg2/dL2 (suco de laranja) e 34,5 mg2/dL2 (café da manhã), respectivamente, e a área sob a curva foi 2.433 mg/dL.min. (água), 2.577 mg/dL.min. (suco de laranja) e 2.506 mg/dL.min. (café da manhã), 1.203 mg/dL.min. (água), 1.052 mg/dL.min. (suco de laranja) e 1.128 mg/dL.min. (café da manhã), respectivamente. Não houve diferença significante entre os três diferentes testes (p > 0,05). Conclusão: Os níveis séricos de cálcio, fósforo e produto cálcio-fósforo evoluíram de forma semelhante nas três formas de ingestão de carbonato de cálcio.


Subject(s)
Humans , Female , Adult , Middle Aged , Young Adult , Phosphorus/blood , Calcium Carbonate/administration & dosage , Calcium/blood , Dietary Supplements , Hypoparathyroidism/therapy , Phosphorus/administration & dosage , Reference Values , Thyroidectomy/adverse effects , Thyroidectomy/methods , Time Factors , Calcium Carbonate/blood , Water , Calcium/administration & dosage , Analysis of Variance , Fasting , Treatment Outcome , Cross-Over Studies , Breakfast , Fruit and Vegetable Juices
8.
Actual. osteol ; 13(3): 198-206, Sept - DIc. 2017. graf, tab
Article in Spanish | LILACS | ID: biblio-1117027

ABSTRACT

La osteoporosis afecta al 6-7% de la población masculina. Es alta la proporción de pacientes con fracturas sin diagnóstico previo de esta enfermedad. La mortalidad luego de una fractura es mayor en hombres que en población femenina; a pesar de esto, la mayoría de los pacientes no reciben tratamiento. Los fármacos aprobados, en nuestro medio, para tratar la osteoporosis masculina son: bifosfonatos, teriparatida y ranelato de estroncio. El objetivo de este estudio fue evaluar el efecto del ranelato de estroncio sobre la densidad mineral ósea en hombres después de 1 año de tratamiento. Se incluyeron los registros de 20 hombres de 67,8±3,0 años, tratados con ranelato de estroncio (2 g/día) durante 1 año. Todos los pacientes presentaban un T-score inferior a -2,5 en cadera o columna vertebral o un T-score inferior a -2,0 y factores de riesgo de fractura. No hubo modificación de parámetros de laboratorio luego del tratamiento (calcemia, calciuria, fósforo sérico, parathormona, 25(OH)vitamina D, fosfatasa alcalina y desoxipiridinolina) en relación a los basales. Luego del tratamiento con ranelato de estroncio se observó incremento de la densidad mineral ósea en columna lumbar: 0,953±0,029 versus 0,997±0,030 g/cm2 (p=0,0068), cuello femoral: 0,734±0,013 versus 0,764±0,016 g/cm2 (p=0,0084) y cadera total: 0,821±0,02 versus 0,834±0,02 g/cm2 (p=0,0419). Conclusión: el tratamiento con ranelato de estroncio produjo un incremento significativo de la densidad mineral ósea en columna lumbar y fémur proximal en hombres con osteoporosis. (AU)


Osteoporosis affects 6-7% of the male population. The proportion of patients with fragility fractures but without diagnosis of the disease is high. Mortality after hip fracture is higher in men than in women; in spite of this, most patients are left without treatment for osteoporosis. Drugs approved, for the treatment of osteoporosis in our country are bisphosphonates, teriparatide, and strontium ranelate (SrR). The objective of this study was to evaluate the effect of SrR on axial BMD in men after one year of treatment. We obtained pertinent data from medical registries of 20 men aged 67,8±3,0 years, treated with oral SrR (2 g/day) for 12 months. All patients had a T-score below -2,5 at the hip or the lumbar spine, or a T-score below -2,0 and one or more risk factors for fracture. The levels of serum calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D, or PTH, or urinary calcium and desoxipyridinoline remained unchanged following SrR administration. After treatment with SrR there were significant increases in BMD at the lumbar spine: 0,953±0,029 versus 0,997±0,030 g/cm2 (p=0,0068), femoral neck: 0,734±0,013 versus 0,764±0,016 g/cm2 (p=0.0084), and total hip: 0,821±0,02 versus 0,834±0,02 g/cm2 (p=0,0419). Conclusion: in osteoporotic men, treatment with SrR significantly increases BMD in the lumbar spine and the proximal femur. (AU)


Subject(s)
Humans , Male , Aged , Osteoporosis/drug therapy , Strontium/chemistry , Bone Diseases, Metabolic/drug therapy , Bone Density/drug effects , Organometallic Compounds , Osteoporosis/diagnosis , Argentina , Strontium/administration & dosage , Testosterone/therapeutic use , Thiophenes , Vitamin D/administration & dosage , Bone Diseases, Metabolic/metabolism , Bone Diseases, Metabolic/blood , Body Mass Index , Sex Factors , Calcium/administration & dosage , Retrospective Studies , Risk Factors , Bone Density Conservation Agents/therapeutic use , Osteoporotic Fractures , Hypogonadism/complications
9.
Actual. osteol ; 13(3): 243-250, Sept - DIc. 2017. ilus, tab
Article in Spanish | LILACS | ID: biblio-1117571

ABSTRACT

La hipercalcemia es un trastorno común que representa aproximadamente el 0,6% de todas las admisiones médicas agudas. El hiperparatiroidismo primario (HPTP) y las neoplasias malignas son las dos causas más comunes de elevación de los niveles séricos de calcio; constituyen, en conjunto, alrededor del 90% de todos los casos. La presentación sintomática clásica de la hipercalcemia se observa con relativa poca frecuencia en el mundo desarrollado; la presentación más común es la detección asintomática en las pruebas bioquímicas. Sin embargo, en casos raros, el HPTP puede desarrollar hipercalcemia aguda, grave y sintomática, llamada crisis hipercalcémica (CH). Esta condición se asocia a alteraciones profundas en el estado mental y las funciones cardíaca, renal y gastrointestinal en presencia de concentraciones marcadamente elevadas de calcio sérico y paratohormona (PTH). Mientras que algunas elevaciones en el calcio sérico pueden ser bien toleradas, los síntomas de la CH son severos. Si el tratamiento se retrasa, la CH puede provocar la muerte. Describimos el caso de un paciente masculino que ingresa en la unidad de cuidados críticos por una CH secundaria a un HPTP por adenoma paratiroideo. (AU)


Hypercalcaemia is a most common disorder, accounting for approximately 0,6% of all acute medical admissions. Primary hyperparathyroidism (PHPT) and malignancy are the two most common causes of increased serum calcium levels, together accounting for about 90% of all cases. The classical symptomatic presentation of hypercalcaemia is seen relatively rarely in the developed world, the most common presentation being asymptomatic and detected following on biochemical testing. However, in rare cases HPTP can result in acute, severe and symptomatic hypercalcemia, called hypercalcemic crisis (HC). This condition is associated with profound disturbances in mental status, and cardiac, renal, and gastrointestinal function in the presence of markedly increased serum calcium and parathyroid hormone (PTH) concentrations. While some elevations in serum calcium can be well tolerated, symptoms of HC are severe. If treatment is delayed, HC can result in death. We describe herein a case of a male patient who was admitted to the intensive care unit as a consequence of HC resulting from elevated PTH, secondary to a parathyroid adenoma. We describe the case of a male patient who was admitted to the critical care unit for a HC mediated by PTH secondary to a parathyroid adenoma. (AU)


Subject(s)
Humans , Male , Middle Aged , Parathyroid Neoplasms/complications , Parathyroid Glands/pathology , Hyperparathyroidism, Primary/complications , Hypercalcemia/chemically induced , Parathyroid Hormone/metabolism , Parathyroid Hormone/blood , Parathyroid Neoplasms/surgery , Parathyroid Neoplasms/diagnostic imaging , Parathyroid Glands/surgery , Vitamin D Deficiency/blood , Calcitriol/administration & dosage , Calcium Gluconate/administration & dosage , Weight Loss , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Calcium/administration & dosage , Calcium/blood , Renal Dialysis , Cholecalciferol/administration & dosage , Dehydration , Diuretics/administration & dosage , Hyperparathyroidism, Primary/surgery , Hyperparathyroidism, Primary/diagnosis , Cinacalcet/administration & dosage , Pamidronate/administration & dosage , Crystalloid Solutions/administration & dosage , Hypercalcemia/diagnosis , Hypercalcemia/drug therapy , Hypercalcemia/blood
10.
Arch. endocrinol. metab. (Online) ; 61(5): 447-454, Sept.-Oct. 2017. tab
Article in English | LILACS | ID: biblio-887588

ABSTRACT

ABSTRACT Objective The aim of this study was to evaluate the use of prophylactic oral calcium after total thyroidectomy in the prevention of symptomatic hypocalcemia, and to develop a rational strategy of oral calcium supplementation following this type of surgery. Subjects and methods Prospective study including 47 patients undergoing total thyroidectomy from January 2007 to February 2012. The patients were allocated to one of the following groups: I (no postoperative calcium) or II (oral calcium 3 g per day). Oral calcium was started at the first postoperative day and administered until the sixth postoperative day. The patients were followed up for a minimum of 6 months and evaluated with a minimum of five measurements of ionized calcium: preoperative, 16 hours after surgery, seventh postoperative day, and at postoperative days 90 (PO90) and 180 (PO180). The cohort included three men and 44 women, of whom 24 (51.9%) had benign thyroid disease, and 23 had suspected or confirmed malignant disease. Results When compared with Group II, Group I had significantly higher rates of postoperative biochemical hypocalcemia at PO1 and PO180, and of symptomatic hypocalcemia at PO1, PO7, and PO90. Other data were not significantly different between the groups. Conclusion We conclude that postoperative calcium supplementation effectively prevents symptomatic and biochemical hypocalcemia after total thyroidectomy, and can be safely used after this procedure. The presented strategy of oral calcium supplementation may be implemented in a viable manner.


Subject(s)
Humans , Male , Female , Thyroidectomy/methods , Calcium/administration & dosage , Dietary Supplements , Hypocalcemia/prevention & control , Postoperative Care , Thyroid Diseases/surgery , Thyroidectomy/adverse effects , Biomarkers/blood , Administration, Oral , Prospective Studies
11.
Braz. j. infect. dis ; 21(3): 270-275, May-June 2017. tab
Article in English | LILACS | ID: biblio-839222

ABSTRACT

ABSTRACT Background: The increase in life expectancy for patients living with human immunodeficiency virus (HIV) infection has resulted in health complications related to a chronic disease. Objectives: To evaluate the prevalence of bone mineral density (BMD) alterations and vitamin D concentrations in HIV-infected children and adolescents and to verify the variations in those parameters during a 12-month interval. Methods: A prospective cohort study with a dual period of evaluation was conducted in 57 patients perinatally HIV-infected and one patient with sexual abuse in early infancy. Demographic, anthropometric, pubertal stage, viral load, T CD4+ cell count and antiretroviral therapy were evaluated. Biochemical tests and total body (TB) and lumbar spine (L1-L4) bone density evaluations by dual X-ray absorptiometry (DXA) were performed. Calcium or vitamin D supplements were prescribed if reduction in BMD or deficiency for vitamin D was detected. Results: 58 patients (ages 5.4-18.3 years; 60.3% girls) were included (T0); 55 patients were reevaluated after 12 (±3) months (T1). Low bone mass for chronological age was found in 6/58 (10.4%) and 6/55(10.9%) patients at T0 and at T1, respectively. There was no statistical relationship between z-scores for BMD (BMD z-score) and the variables sex, fracture history, family history of osteoporosis, physical activity and pubertal stage. There was a relation between BMD z-score alterations for TB and HIV viral load at T1 (p = 0.016). There was no association between duration or classes of antiretroviral therapy and bone density. The mean value of vitamin D in T0 was 23.43 ng/mL ± 2.015 and in T1 22.1 ng/mL ± 0.707 and considered insufficient levels for this population. Conclusion: Patients infected with HIV are at risk for BMD alterations and lower vitamin D serum concentrations; both of these variables should be evaluated at routine examinations in order to improve both prevention and therapeutic planning.


Subject(s)
Humans , Male , Female , Child , Adolescent , Vitamin D/blood , Bone Density/physiology , HIV Infections/complications , Calcium/administration & dosage , Vitamin D/administration & dosage , Absorptiometry, Photon , HIV Infections/physiopathology , HIV Infections/blood , Prevalence , Prospective Studies , CD4 Lymphocyte Count , Viral Load
12.
Actual. osteol ; 13(1): 9-16, Ene - Abr. 2017. tab
Article in Spanish | LILACS | ID: biblio-1118618

ABSTRACT

Tanto el ranelato de estroncio (RSr) como el denosumab (Dmab) son eficaces en el tratamiento de la osteoporosis (OP) posmenopáusica (PM). El efecto de cada fármaco por separado sobre la densidad mineral ósea (DMO) ha sido estudiado recientemente. Con ambas drogas se observó, al año de tratamiento, un aumento significativo de la DMO en columna lumbar (CL), cuello femoral (CF) y cadera total (CT). En este trabajo comparamos la respuesta densitométrica al año de tratamiento con una y otra droga. Utilizamos los registros de 425 pacientes PMOP tratadas con Dmab y 441 tratadas con RSr. En cada paciente analizamos el porcentaje de cambio; se clasificaron como respondedoras aquellas que mostraron un cambio ≥3%. Adicionalmente se comparó la respuesta en pacientes no previamente tratadas con bifosfonatos (BF-naïve) en comparación con pacientes que habían recibido previamente un BF. Al analizar el grupo completo para Dmab, el porcentaje de pacientes respondedoras fue de 68,4% en CL, 63,3% en CF y 49,3% en CT. Por otro lado, en el grupo de pacientes tratadas con RSr, el porcentaje de respondedoras (53,8% en CL, 40,0% en CF y 35,6% en CT) fue estadísticamente menor. Cuando comparamos la respuesta entre las pacientes BF-naïve que recibieron RSr o Dmab, el Dmab indujo mayor respuesta en CL y CF que el grupo RSr, sin diferencias en CT. Cuando se analizaron los subgrupos BF-previo, las tratadas con Dmab mostraron mayor respuesta en todas las regiones. Conclusión: en pacientes con OP-PM, el tratamiento con Dmab produjo mayores incrementos densitométricos que el RSr, siendo el porcentaje de pacientes respondedoras mayor con Dmab que con RSr. (AU)


Both strontium ranelate (SrR) and denosumab (Dmab) are effective in the treatment of postmenopausal osteoporosis (PMOP). The effect of each drug on bone mineral density (BMD) has been studied separately by us. With both treatments, there was a significant increase after one year of treatment at the lumbar spine (LS) and hip. In this paper we compared the densitometric response after one year of treatment with both drugs used separately. We used the clinical records of 425 PM patients treated with Dmab and 441 treated with SrR. For each patient we analyzed the percentage of change; those who showed a change ≥3% were classified as responders. Additionally, the response was compared in patients not previously treated with bisphosphonates (BP-naïve) compared to patients who had previously received a BP. When analyzing the complete group for Dmab, the percentage of "responders" was 65.2% at the LS, 62.9% at the femoral neck (FN) and 47.4% at the total hip (TH). On the other hand, in the group of patients treated with SrR the percentage of responders (53.8% at the LS, 40.0% at the FN and 35.6% at the TH) was statistically lower. When comparing the response between in BF-naïve patients receiving RSr or Dmab, Dmab induced a greater response at the LS and FN than the RSr group, with no statistical differences at the TH. When the subgroups with prior BP treatment were analyzed, those treated with Dmab showed greater response in all regions. Conclusion: in patients with PMOP treatment with Dmab produced greater densitometric increments than SrR, and the percentage of responders was higher with Dmab than with SrR. (AU)


Subject(s)
Humans , Female , Middle Aged , Aged , Aged, 80 and over , Strontium/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Denosumab/therapeutic use , Phosphates/blood , Strontium/administration & dosage , Strontium/chemistry , Vitamin D/administration & dosage , Biomarkers , Bone Density/drug effects , Fractures, Stress/prevention & control , Osteocalcin/blood , Osteoporosis, Postmenopausal/blood , Calcium/administration & dosage , Calcium/blood , Retrospective Studies , Teriparatide/therapeutic use , Densitometry , Diphosphonates/therapeutic use , Alkaline Phosphatase/blood , Bone Density Conservation Agents/therapeutic use , Femur Neck/drug effects , Denosumab/administration & dosage , Treatment Adherence and Compliance , Hip , Lumbosacral Region
13.
Evid. actual. práct. ambul ; 20(4): 102-104, 2017. ilus
Article in Spanish | LILACS | ID: biblio-1097209

ABSTRACT

Si bien los niveles bajos de vitamina D se han asociado con varios resultados de interés en salud, aún resulta motivo de controversia qué significa un nivel bajo, cual es la utilidad de su suplementación y cuales son sus potenciales efectos adversos. En ese contexto, se realizó en el Servicio de Medicina Familiar y Comunitaria del Hospital Italiano un taller de discusión denominado "Actividad ECCO" (Evidencia Científica en la Clínica Cotidiana) en la que fueron presentados los resulta-dos de estudios identificados que hubieran comparado el uso de vitamina D (con o sin suplementación de calcio) ver-sus placebo, con el objetivo de discutir cuál es la evidencia actual para el rastreo de deficiencia de vitamina D y para, eventualmente, recomendar o no su suplementación. Este artículo resume la evidencia identificada y las conclusiones consensuadas en dicha actividad. (AU)


Although low levels of vitamin D have been associated with several health outcomes, it is controversial what a low level means, the usefulness of its supplementation and its potential adverse effects. In this context, a workshop called "ECCO Activity" (Scientific Evidence in the Daily Clinic) was held in the Family and Community Medicine Division of Hospital Italiano de Buenos Aires, where the results of identified studies that compared the use of vitamin D (with or without calcium supplementation) versus placebo, with the aim of discussing what is the current evidence for screening of vitamin D deficiency and to, eventually, recommend or not its supplementation. This article summarizes the identified evidence and the agreed conclusions in that activity. (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Avitaminosis/diagnosis , Vitamin D/adverse effects , Osteoporosis/drug therapy , Exocrine Pancreatic Insufficiency/complications , Phenobarbital/adverse effects , Phenytoin/adverse effects , Sunscreening Agents/adverse effects , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D/therapeutic use , Accidental Falls/prevention & control , Accidental Falls/statistics & numerical data , Biomarkers , Gastric Bypass/adverse effects , Inflammatory Bowel Diseases/complications , Celiac Disease/complications , Calcium/administration & dosage , Calcium/therapeutic use , Risk , Adrenal Cortex Hormones/adverse effects , Irritable Bowel Syndrome/complications , Anti-Retroviral Agents/adverse effects , Hepatic Insufficiency/complications , Renal Insufficiency, Chronic/complications
14.
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci Torres; Oliveira Junior, Múcio Tavares de; Kalil Filho, Roberto. Manual da condutas da emergência do InCor: cardiopneumologia / IInCor Emergency Conduct Manual: Cardiopneumology. São Paulo, Manole, 2ª revisada e atualizada; 2017. p.658-665.
Monography in Portuguese | LILACS | ID: biblio-848491
15.
Actual. osteol ; 12(2): 107-125, 2016. tab
Article in Spanish | LILACS, BINACIS, UNISALUD | ID: biblio-1372377

ABSTRACT

La osteoporosis inducida por glucocorticoides (OIC) es la causa más común de osteoporosis secundaria. La pérdida ósea se produce en forma temprana, en los primeros meses siguientes a la introducción de los glucocorticoides (GC), dependiendo de la dosis diaria. La patogénesis es multifactorial y el principal efecto deletéreo es la inhibición de la formación ósea. Los GC inducen fracturas por fragilidad ósea, especialmente en la columna vertebral, y esto genera incapacidad funcional. En los últimos años se han publicado algunas guías internacionales elaboradas por consenso para la prevención y el tratamiento de la OIC. La Sociedad Argentina de Osteoporosis designó a un grupo de trabajo para elaborar una guía propia y actualizada para el diagnóstico, la prevención y el tratamiento de la OIC (GE-OIC-SAO). (AU)


Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. It occurs early, with rapid bone loss in the first few weeks after the initiation of the treatment, with a rate that is dependent mainly on the daily dose. While the pathogenesis is multifactorial, the highest inhibitory effect occurs on bone formation. Glucocorticoids induce fragility fractures, especially in spine, generating functional disability. In recent years, there have been some international guidelines developed by consensus for the prevention and treatment of GIO. The Argentinean Osteoporosis Society appointed a working group to prepare a national guide updating the diagnosis, prevention and treatment of GIO. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Osteoporosis/diagnosis , Osteoporosis/chemically induced , Osteoporosis/prevention & control , Osteoporosis/drug therapy , Osteoporosis/therapy , Glucocorticoids/adverse effects , Osteogenesis Imperfecta/chemically induced , Osteoporosis/physiopathology , Osteoporosis/epidemiology , Vitamin D/administration & dosage , Calcium/administration & dosage , Practice Guidelines as Topic , Teriparatide/administration & dosage , Densitometry , Diphosphonates/administration & dosage , Vertebroplasty , Osteoporotic Fractures/chemically induced , Glucocorticoids/administration & dosage
16.
Med. interna (Caracas) ; 32(1): 56-63, 2016. tab
Article in Spanish | LILACS, LIVECS | ID: biblio-1009608

ABSTRACT

Para mantener un esqueleto sano y mineralizado es de importancia crítica tener una fuente adecuada de vitamina D, que puede conseguirse mediante la exposición solar o la dieta. Se ha observado un aumento de la prevalencia del déficit de Vitamina D que se ha extendido a distintos grupos de edad y diferentes regiones, y ha alcanzado proporciones epidémicas. Estudios recientes han demostrado la importancia de la Vitamina D en la función neuromuscular y su déficit se ha relacionado con alteraciones funcionales y riesgo de caídas en ancianos. La vitamina D es esencial para la absorción normal del calcio en el intestino y tiene un papel fundamental en la mineralización del hueso. Objetivo: Determinar los valores de 25-hidroxivitamina D (25-OH D3) en hombres con baja masa ósea. Materiales y métodos: Se estudiaron sujetos masculinos con baja masa ósea que acudieron a la Unidad de Investigación UNILIME-UC Hospital Universitario "Dr. Ángel Larralde" entre Junio a Diciembre 2015, la muestra quedó constituida por 47 sujetos con criterios de inclusión (> 60 años con baja masa ósea (osteopenia-osteoporosis) por densitometría ósea (DEXA), en ausencia de enfermedades que determinan hipovitaminosis. A los mismos se les midió calcio sérico y 25 -hidroxivitamina D ( 25 -OH D3) este último se determinó por inmmuno ensayo (OCTEIA 25 -hidroxi vitamina D. IDS.UK). Se tomaron muestras de sangre venosa en ayuno, se congelaron a -70 °C y se midió por duplicado en el mismo tiempo. Los resultados se analizaron con programa SPSS.20 para Windows, utilizando técnicas de análisis descriptivos y para la significancía estadística, el coeficiente correlación de Pearson. Resultados: Se estudiaron 47 hombres con un promedio de edad de 66,28± 5,17 años, con valores promedio de calcio sérico de 8,88±0.38 mg/dl y con baja masa osea por DEXA a nivel de cuello de fémur (CF) de 0,870 g/cm3 con T score -1.5 y a nivel de columna lumbar L1-L4 de 0,917 g/cm3 con T score -1.8. Valores promedio de Vitamina D (25-OH D3) de 28,72±5,33 ng/ml (valor mínimo 18 ng/ml y valor máximo 39,60 ng/ml), observando un 38,30% (n=18) con valores inferiores de 30 ng/dl; de los cuales el 23,5% (n=11) presentaron valores entre 20 - 30 ng/ml catalogados como sujetos con deficit relativo de 25-OH D3 y un 14,8% (n=7) con valores inferiores a 20 ng/ml catalogados como sujetos con insuficiencia de 25-OH D3. Al correlacionar los valores de 25-OH D3 con la edad se observó una relación estadisticamente significativa (p<0,05), no asi con los niveles de calcio sérico (p=0.2), con DEXA CF (p=0.18) y con DEXA L1- L4 (p= -0,15). Conclusiones: La prevalencia de la disminución de vitamina D (25-OH D3) está sobrestimada, sobre todo en los paises tropicales donde se supone que contamos con uno de los principales factores que influyen en mantener dichos valores como es la exposición solar. En este estudio se observa una alta prevalencia de ipoavitaminosis (deficiencia e insuficiencia) de Vitamina D (38,3%). Por lo cual recomendamos se considere (AU)


To maintain a healthy mineralized skeleton is critically important to have an adequate supply of vitamin D, which can be achieved by sun exposure or diet. There has been an increase in the prevalence of vitamin D deficiency that has spread to different age groups and different regions, and has reached epidemic proportions. Recent studies have shown the importance of vitamin D in the neuromuscular function, and its deficit has been associated with functional alterations and risk of falls in the elderly. Vitamin D is essential for normal calcium absorption in the intestine and plays a key role in bone mineralization. Objective: To determine the values of 25 -hydroxyvitamin D (25 - OH D3) in men with low bone mass. Methods: Male patients with low bone mass who came to the Research Unit UNILIME -UC University Hospital " Angel Larralde" were studied from June to Diciemnbre 2015; the sample consisted of 47 subjects with theses inclusion criteria. >60 years with low bone mass (osteopenia - (osteoporosis) by bone densitometry (DEXA ) in the absence of diseases that determine hipovitaminosis. Serum calcium and 25 hydroxyvitamin D (25 -OH D3 ) were measured by enzymeinmmunoassay (25 -hydroxy vitamin D. OCTEIA IDS.UK ) venous blood samples in fasting state , frozen at - 70° C and measured in duplicate at the same time. the results were analyzed with SPSS.20 program for Windows, using descriptive analysis techniques and statistical significance the Pearson correlation coefficient. Results: the average age was 66.28 ± 5.17 years (minimum value of 61 years and maximum 71 years ), with average values of serum calcium of 8.88 ± 0.38 mg / dl and low bone mass by DEXA level Femur neck ( CF ) of 0.870 g / cm3 with Tscore -1.5 and level L1- L4 lumbar spine of 0.917 g / cm3 with Tscore -1.8. average Vitamin D values (25 - OHD3) of 28.72 ± 5.33 ng / ml (minimum value of 18 ng/ ml and maximum value 39.60 ng / ml), observing a 38.30 % (n = 18) with values lower than 30 ng / dl ; of which 23.5 % (n = 11) showed values between 20 to 30 ng / ml classified as subjects with relative deficit of 25 - OH D3 and 14.8 % (n = 7) with values lower than 20 ng / ml classified as failure subjects with 25 - OH D3. By correlating the values of 25 - OH D3 with age A statistically significant relationship (p < 0.05) was observed, but not with serum calcium levels (p = 0.2) with DEXA CF (p = 0.18) and with DEXA L1 -L4 (p = -0.15). Conclusions: Decrease of the prevalence of vitamin D (25 - OHD3) is overestimated, especially in tropical countries where sun exposure happens. In this study a high prevalence of Vit D hypovitaminosis (deficiencyand insufficiency) Vitamin D (38.3 %) was found. Therefore we recommend the determination of serum Vitamin D is considered in male subjects over 60 years and which have low bone mass(AU)


Subject(s)
Humans , Vitamin D Deficiency/complications , Bone Density , Calcium/administration & dosage , Dietary Supplements , Osteoporotic Fractures , Internal Medicine
17.
Int. j. morphol ; 33(2): 725-731, jun. 2015. ilus
Article in English | LILACS | ID: lil-755535

ABSTRACT

The aim of this investigation was to evaluate the potential effects of the systemically delivered combination of calcium, zinc and vit-d supplementation of the locally applied alloplastic bone graft. 28 male Wistar albino rats were used in this study. In each animal, bone defects (10 mm length ¥ 3 mm width ¥ 2 mm depth) were created in the tibias. The animals were divided into four groups. In Group 1 (Control Group) rats were fed with standard rat diet. In Group 2 (Calcium Group) rats received calcium carbonate (15 mg/kg body weight) suspended in saline. In Group 3 (Calcium/Zinc Group) rats received calcium carbonate (15 mg/kg body weight) and zinc sulfate (4 mg/kg body weight) suspended in saline. In Group 4 (Calcium/Vitamin D Group) rats received calcium carbonate (15 mg/kg body weight) and Vitamin D (500 IU/kg body weight) suspended in olive oil. Histopathological analysis of samples was performed to evaluate the process of osteoblastic activity, matrix formation, trabecular bone formation and myeloid tissue in bone defects. Total amounts of osteoblastic activity, matrix formation, trabecular bone formation and myeloid yissue in Ca Group (p= 0.002), Ca/Zinc Group (p= 0.002), and Ca/Vit.D Group (p= 0.001) were significantly higher than in Control Group. The total amounts of Ca/Vit.D Group were significantly different than Control Group and Ca Group. The results of the present study indicated that the oral calcium carbonate supplementation combination with zinc may have systemic effects on accelerating bone regeneration in alloplastic bone grafted tibial defects. Further human studies involving long-term follow up and different type of bone grafts should be conducted.


El objetivo de esta investigación fue evaluar los efectos potenciales de la combinación sistémica de calcio, zinc y vitamina D como suplemento de la aplicación local de un injerto óseo aloplástico. Fueron utilizadas 28 ratas Wistar albinas (machos). En cada animal, se crearon defectos óseos en las tibias (cuyas medidas fueron: 10 mm de longitud x 3 mm de ancho x 2 mm de profundidad). Los animales fueron divididos en cuatro grupos. En el Grupo 1 (control) las ratas fueron alimentadas con una dieta estándar. En el Grupo 2 (grupo de calcio) las ratas recibieron carbonato de calcio (15 mg/kg de peso corporal) suspendido en solución salina. En el Grupo 3 (grupo de calcio/zinc) las ratas recibieron carbonato de calcio (15 mg/kg de peso corporal) y sulfato de zinc (4 mg/kg de peso corporal) suspendido en solución salina. El Grupo 4 (calcio/vitamina D) recibió carbonato de calcio (15 mg/kg de peso corporal) y vitamina D (500 UI/kg de peso corporal) suspendidos en aceite de oliva. Se realizó un análisis histopatológico de las muestras para evaluar el proceso de actividad osteoblástica, formación de la matriz, hueso trabecular y tejido mieloide en defectos óseos. Las cantidades totales de actividad osteoblástica, formación de matriz, de hueso trabecular y tejido mieloide en los grupos Calcio (p= 0,002), Calcio/Zinc (p= 0,002), y Calcio/Vitamina D (p= 0,001) fueron significativamente mayores que en el grupo de control. Las cantidades totales de Calcio/Vitamina D Grupo fueron significativamente diferentes de los grupos Control y Calcio. Los resultados del presente estudio indican que lacombinación de suplementos de carbonato de calcio por vía oral con zinc puede tener efectos sistémicos sobre la aceleración de la regeneración ósea en defectos tibiales con injertos aloplásticos. Deben llevarse a cabo otros estudios en humanos, que involucren un largo plazo de seguimiento y también diferentes tipos de injertos óseos.


Subject(s)
Animals , Rats , Bone Transplantation , Dietary Supplements , Tibia/pathology , Wound Healing/drug effects , Bone Substitutes , Calcium/administration & dosage , Rats, Wistar , Tibia/surgery , Vitamin D/administration & dosage , Wound Healing/physiology , Zinc/administration & dosage
18.
Rev. bras. cir. cardiovasc ; 29(2): 249-254, Apr-Jun/2014. tab, graf
Article in Portuguese | LILACS | ID: lil-719408

ABSTRACT

O paradoxo do cálcio foi pela primeira vez citado em 1966 por Zimmerman et al. A partir daí, ganhou grande interesse por parte da comunidade científica internacional devido ao fato da ausência do íon cálcio produzir na célula muscular cardíaca dano semelhante à lesão de isquemia-reperfusão. Apesar de não serem conhecidos todos os mecanismos envolvidos no processo da lesão celular no paradoxo do cálcio, a conexão intercelular mantida somente pelo nexus parece ter papel chave na fragmentação celular. A adição de pequenas concentrações de cálcio, bloqueadores de canal de cálcio, hiponatremia ou hipotermia são importantes para evitar que haja lesão celular no momento da reperfusão com soluções com concentração fisiológica de cálcio.


The calcium paradox was first mentioned in 1966 by Zimmerman et al. Thereafter gained great interest from the scientific community due to the fact of the absence of calcium ions in heart muscle cells produce damage similar to ischemia-reperfusion. Although not all known mechanisms involved in cellular injury in the calcium paradox intercellular connection maintained only by nexus seems to have a key role in cellular fragmentation. The addition of small concentrations of calcium, calcium channel blockers, and hyponatraemia hypothermia are important to prevent any cellular damage during reperfusion solutions with physiological concentration of calcium.


Subject(s)
Animals , Humans , Rats , Calcium/metabolism , Heart Injuries/metabolism , Myocytes, Cardiac/metabolism , Adenosine Triphosphate/metabolism , Cell Membrane Permeability , Caffeine/adverse effects , Calcium Channel Blockers/pharmacology , Calcium/administration & dosage , Dinitrophenols/metabolism , Glycocalyx/metabolism , Heart Failure/etiology , Heart Injuries/etiology , Heart Injuries/pathology , Myocardial Reperfusion Injury/metabolism , Myocardium/metabolism , Sodium/physiology , Time Factors
19.
J. bras. nefrol ; 36(2): 132-138, Apr-Jun/2014. tab, graf
Article in Portuguese | LILACS | ID: lil-714666

ABSTRACT

Introdução: Há poucos dados na literatura sobre a suplementação de vitamina D e cálcio e o desenvolvimento de cálculos renais. Objetivo: Avaliar o efeito de doses elevadas de vitamina D3 (V), com suplemento de cálcio (Ca) no desenvolvimento de litíase em modelo experimental. Métodos: Pastilhas foram inseridas na bexiga de ratos, que receberam V com ou sem Ca. Ratos foram divididos em seis grupos: 1. Sham; 2. Controle com pastilha, 3. Controle com V, 4. Pastilha + V, 5. Pastilha + Ca e 6. Pastilha + Ca + V. Resultados: Observou-se 50% e 17% de redução na formação de cálculos, respectivamente nos grupos 5 e 6 em comparação ao grupo 2 (p < 0,005). Não foram observadas hipercalcemia ou hipercalciúria em todos os grupos. Encontramos no grupo 6 (p = 0,03) uma redução significativa na calciúria. Conclusão: A administração de V associada com Ca diminuiu significantemente a formação de cálculos e reduziu significantemente a calciúria, sugerindo uma interferência benéfica na fisiopatologia litogênica. .


Introduction: There is little information in the literature relating supplementary oral usage of vitamin D and calcium to the development of kidney stones. Objective: To evaluate the effect of high dose, 200 IU of vitamin D3 (V) with calcium supplementation (Ca). Methods: Experimental model consists of insertion of pellets into the bladder of rats. V was administered for 30 days with or without Ca. The rats were divided in 6 groups: 1. Sham, 2. Pellets control; 3. V control; 4. Pellets + V; 5. Pellets + Ca and 6. Pellets + Ca + V. Results: 50% and 17% decreases bladder stones formation in groups 5 and 6, p < 0.005 comparing with the group 2 were observed. There was no hypercalcemia or hypercalciuria in all groups. We observed a significant decrease in calciuria in group 6 (p = 0.03). Conclusion: The administration of the V associated with Ca significantly decreased the formation of stones and caused a significant reduction in urinary calcium, suggesting a protection in the lithogenic pathophysiology. .


Subject(s)
Animals , Rats , Calcium/administration & dosage , Cholecalciferol/adverse effects , Nephrolithiasis/chemically induced , Vitamins/adverse effects , Cholecalciferol/administration & dosage , Dietary Supplements , Disease Models, Animal , Drug Overdose , Rats, Wistar , Vitamins/administration & dosage
20.
Rev. chil. pediatr ; 84(6): 672-680, dic. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-703291

ABSTRACT

Introducción: La hipocalcemia es un hallazgo infrecuente en los pacientes atendidos en los servicios de urgencia pediátricos. El raquitismo se puede presentar como una hipocalcemia crónica la mayoría de las veces asintomática, sin embargo, algunos pacientes presentan tetanias hipocalcémica. Objetivo: Presentar el caso clínico de una niña con raquitismo hipocalcémico, cuyo diagnóstico fue tardío. Caso clínico: Prescolar de 2 años 5 meses con alteración en la marcha, mal incremento ponderal, espasmos musculares y signos de raquitismo activo. Los exámenes revelaron hipocalcemia severa, normofosfemia, fosfatasa alcalina y PTH elevada y niveles normales de 25 hidroxivitamina D. Se manejó con calcio y calcitriol, y se diagnosticó raquitismo vitamina D dependiente tipo I. Conclusión: Los síntomas y signos clásicos de raquitismo, así como la hipocalcemia, deben hacernos plantear hoy en día el diagnóstico de raquitismo. Un mejor conocimiento de esta patología permitirá evitar el retraso en el diagnóstico y un tratamiento más oportuno.


Introduction: Hypocalcemia is rare in patients attending pediatric emergency services. Rickets can present as a chronic hypocalcemia often asymptomatic, poor growth rate, psychomotor delay and bone abnormalities, but some patients may present tetanic seizures. Although its incidence has decreased, a resurgence of rickets has been described. Objective: To present a case of a child with hypocalcemic rickets, whose diagnosis was delayed. Case report: Preschool of 2,4 years old with gait disturbance, poor growth rate, muscle spams and signs of active rickets. Laboratory results showed hypocalcemia, normophosphemia, alkaline phosphatase, high PTH and normal 25-hydroxyvitamin D levels. She received treatment with calcium and calcitriol and had a good response; Vitamin D dependent rickets type I was diagnosed. Conclusion: Classics signs and symptoms of rickets, as hypocalcemic manifestations, should lead us today to diagnose rickets. Better knowledge of this disease will avoid retarded diagnosis and give a suitable treatment.


Subject(s)
Humans , Female , Child, Preschool , Hypocalcemia/diagnosis , Rickets/diagnosis , Clinical Evolution , Calcium/administration & dosage , Calcitriol/administration & dosage , Calcitriol/deficiency , Diagnosis, Differential , Hypocalcemia/drug therapy , Rickets/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL